Canagliflozin Reveals a Cardioprotective Effect in Acute Myocardial Infarction Management via Modulation of WnT/ β-catenin Pathway | ||
| Cardiovascular Research Prove Journal | ||
| Volume 9, Issue 1, June 2025 PDF (232.96 K) | ||
| Document Type: Abstracts | ||
| DOI: 10.21608/cvrepj.2025.438153 | ||
| Abstract | ||
| Canagliflozin (CANA) is an antidiabetic drug of the sodium-glucose co-transporter 2 inhibitor (SGLT2i) group. CANA was reported to reduce pathological events associated with heart failure. However, the exact mechanism by which CANA positively acts on cardiac tissue requires further elucidation. | ||
|
Statistics Article View: 55 PDF Download: 39 |
||
